Meet CAnswer BioSolutions Limited. CAnswer BioSolutions Limited is finding an answer to cancer, one solution at a time with novel biopsy kits and proprietary AI diagnostic softwares. The TeamOur multidisciplinary team of industry experts is comprised of a cancer surgeon, an AI Scientist, a mathematician, data engineer and economist, and a lawyer. We have won various university innovation and accelerator programmes, are finalists in Converge KickStart Challenge and UK finalists in ESBS champion of Champions (to be held in November). ProblemConventional biopsies cost over £500, need access to operation theatre facilities and are mentally traumatizing for patients. The current diagnostic pipeline has a 6-9-month delay, worsened by the need to travel from islands and rural communities to the mainland highlands. NHS has 1/5 staffing shortage across all boards, leading to further diagnostic delay, often reducing patient prognosis in 70% of all undiagnosed cancer patients.SolutionWe have developed an innovative portable punch biopsy kit that enables surgeons and clinicians to perform punch biopsies outside operating theatres in community settings and with minimal trauma to patients, reducing costs by 90% and waiting times from close to a year to days.Our stand-alone AI diagnostic platform needs less data and training times, while offering a higher accuracy than our competitors, being based on a copyrighted mathematical and statistical scoring system. This makes it very well suited for small and fragmented datasets, like those found in Scotland. CAnswer Lens is free from melanin pigmentation biases that commonly plagues other AI models, allowing us to bring equitable diagnosis to global demographics, free from skin colour limitations. ContactCAnswer BioSolutions Limited websiteCAnswer BioSolutions Limited LinkedIn This article was published on 2025-10-27
